/ Not yet recruitingN/AIIT Efficacy Evaluation and Recurrence Monitoring of Neoadjuvant Therapy and Adjuvant Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.
This project is focusing on who have locally advanced esophageal squamous cell carcinoma and have undergone neoadjuvant and adjuvant therapy, followed by surgical resection. The exclusive MRD (Minimal residual disease) probe consists of an exclusive "molecular label" formulated according to the individual genome mutation profile and 21 critical tumor driver genes. By continuously monitoring each patient's ctDNA dynamics, changes in ctDNA concentration or ctDNA-MRD negative/positive results will serve as the primary indicators to assess the efficacy and prognosis of patients with esophageal squamous cell carcinoma.
100 项与 HaploX Investment Holding Ltd. 相关的临床结果
0 项与 HaploX Investment Holding Ltd. 相关的专利(医药)
100 项与 HaploX Investment Holding Ltd. 相关的药物交易
100 项与 HaploX Investment Holding Ltd. 相关的转化医学